HealthQuill HIV
A new weapon to kill superbugs may be on the horizon after Harvard researchers created a synthetic compound called cresomycin.
Drugs Health

HIV’s shape-shifting protein reveals clues for smarter drug design

A study from the Salk Institute has found HIV’s ability to hijack human cells, uncovering a shape-shifting viral protein that could transform treatments for the.

Read More
ViiV Healthcare, majority owned by GSK, has signed a pact with the UN-backed Medicines Patent Pool (MPP) to enable generic access to its HIV treatment in 133 countries.
Drugs Health Pharma

ViiV to grant generic access to its HIV medicine to benefit 133 nations

HQ Team July 15, 2025: ViiV Healthcare, majority owned by GSK, has signed a pact with the UN-backed Medicines Patent Pool (MPP) to.

Read More
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an “Emergency Humanitarian Waiver” to allow people to continue accessing HIV treatment funded by the US across 55 countries worldwide.
Drugs Health Medical

US ‘humanitarian wavier’ will help deliver life-saving HIV medicines: UN

The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an “Emergency Humanitarian Waiver” to allow.

Read More
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s and 1990s when millions died of the virus, including many in the United States, according to the World Health Organization.
Drugs Health Pharma

US aid pause to take ‘world back to 1980s, 1990s’ on fighting HIV: WHO 

A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.

Read More
About one person every second or 42 million people each year are estimated to contract genital herpes infection worldwide, according to the World Health Organization.
Drugs Health Pharma

1 person contracts genital herpes infection every second in the world

About one person every second or 42 million people each year are estimated to contract genital herpes infection worldwide, according to the World.

Read More
Malaria, HIV, and tuberculosis were among a list of 17 disease-causing pathogens where vaccines need to be developed as a priority to reduce regional disease burden, according to the World Health Organization.
Drugs Health Pharma

Malaria, TB among top diseases where vaccines needed most: WHO 

Malaria, HIV, and tuberculosis were among a list of 17 disease-causing pathogens where vaccines need to be developed as a priority to reduce.

Read More
The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability of a rectal microbicide douche containing the antiretroviral drug tenofovir to prevent HIV infection spread among men.
Drugs Health Pharma

Mid-stage trial of a rectal microbicide for HIV prevention in the US begins 

HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.

Read More
Tuberculosis has emerged as the world’s top infectious disease with about 8.2 million people newly diagnosed with the illness last year — the highest on records since WHO began global monitoring in 1995.
Drugs Health Medical

Tuberculosis was the world’s top infectious disease killer last year

Tuberculosis has emerged as the world’s top infectious disease with about 8.2 million people newly diagnosed with the illness last year — the.

Read More
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.
Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

Read More
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention of HIV.
Drugs Health Pharma

Gilead signs six global pacts to make, sell generic HIV preventive drug

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.

Read More